Align Technology, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Although the request references 2021 Q4, the filing is an annual report; the supplied text does not provide a complete standalone fourth-quarter income statement or cash-flow summary.
Business context
Align designs, manufactures and sells Invisalign clear aligners, iTero intraoral scanners and services, and exocad dental CAD/CAM software. It reports two segments: Clear Aligner and Systems and Services. Clear Aligner generated approximately 82% of FY2021 revenue. The company attributed growth to increased case and scanner volumes, greater digital adoption and expansion of its customer base.
Key financial results
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $3,952.6 million | $2,471.9 million | +59.9% |
| Gross profit / margin | $2,935.4 million / 74.3% | $1,763.2 million / 71.3% | Margin +3.0 percentage points |
| Operating income / margin | $976.4 million / 24.7% | $387.2 million / 15.7% | Operating income +$589.2 million |
| Net income | $772.0 million | $1,775.9 million | Down; FY2020 included a substantial one-time tax benefit |
| Diluted EPS | $9.69 | $22.41 | Down, primarily reflecting the unusual FY2020 tax benefit |
| Operating cash flow | $1,172.5 million | $662.2 million | +$510.4 million |
| Capital expenditures | $401.1 million | $154.9 million | Higher investment in facilities and capacity |
- Segment revenue: Clear Aligner revenue was $3,247.1 million, up 54.5%; Systems and Services revenue was $705.5 million, up 90.4%.
- Volumes: Clear Aligner case shipments rose 54.8% to 2.55 million. Total utilization increased to 20.8 cases per doctor from 16.1.
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $1,296.7 million at year-end, versus $960.8 million in 2020. Current assets were $2,494.1 million and current liabilities $1,924.1 million.
- Debt: No borrowings were outstanding under the $300 million revolving credit facility at year-end. The filing does not identify other outstanding debt in the supplied text.
- Share repurchases: The company repurchased $375.0 million of stock in 2021 and had $725.0 million remaining under its May 2021 authorization at year-end.
Changes versus the prior comparable period
- Revenue growth reflected Clear Aligner volume growth and a higher number of scanners recognized. Systems and Services also benefited from increased service revenue and a mix shift toward higher-priced scanners.
- Gross margin improved in both segments. Management cited Clear Aligner manufacturing efficiencies from higher production volumes and, for Systems and Services, product mix and service revenue, partly offset by higher freight costs.
- SG&A rose to $1,708.6 million from $1,200.8 million, driven primarily by higher compensation and $183.4 million of additional advertising and marketing expense. R&D increased to $250.3 million from $175.3 million.
- Net income comparisons are distorted by FY2020’s approximately $1,493.5 million one-time tax benefit from an intra-entity transfer of intellectual property and fixed assets to Switzerland. FY2021’s effective tax rate was 23.7%, versus a benefit-driven rate of negative 368.6% in 2020.
- FY2021 other income included a $43.4 million gain from an SDC arbitration award. Cash and marketable securities increased, while capital spending and stock repurchases used significant cash.
Outlook, commentary and risks
- Management expects to continue investing in international expansion, GP adoption, consumer demand and orthodontist utilization, including R&D, sales and marketing, manufacturing and treatment-planning capacity. It expects international revenue to grow faster than Americas revenue over the longer term, but provided no specific FY2022 revenue or earnings guidance in the supplied filing text.
- Management expected capital expenditures to exceed $350 million over the next 12 months, principally for facilities and manufacturing capacity, including the planned Poland aligner facility. Purchase commitments totaled $1,278.0 million, of which $731.0 million was payable within 12 months.
- Management cautioned that strong FY2021 growth may not indicate future performance: FY2020 was affected by pandemic-related office closures, while COVID-19 variants, customer capacity, supply delays and changing consumer spending continued to create uncertainty. Inflation in materials, labor, freight and transportation was also expected to pressure margins in 2022.
- Key operating risks include intensifying clear-aligner and scanner competition; dependence on Invisalign and iTero; sole-source suppliers for important materials and components; manufacturing capacity and labor constraints; foreign exchange and international operating exposure; regulatory requirements; and cybersecurity, patient-data privacy and IT-system risks.
- Legal and unusual items: A $16 million securities class-action settlement was expected to be funded by insurance and remained subject to final court approval. Antitrust class actions and an SDC supply-agreement arbitration remained unresolved, with outcomes not estimable by the company. Align and 3Shape settled their patent and antitrust litigation in February 2022 on confidential terms; the settlement was not expected to materially affect ongoing operations or financial results. The company reported no material off-balance-sheet arrangements.
Important facts for investors to verify
- Review the full-year versus Q4 revenue, margins and cash-flow data in the complete filing; the supplied text does not clearly provide a standalone Q4 financial summary.
- Assess how much FY2021 growth came from underlying demand and utilization versus comparison with pandemic-affected FY2020, pricing, promotions, product mix and foreign exchange.
- Monitor gross-margin effects from inflation, freight, facility expansion, capacity utilization and supply-chain dependencies.
- Examine the assumptions behind clear-aligner revenue recognition, especially estimated usage of additional aligners; this was identified as a critical audit matter.
- Track the resolution and potential financial exposure of pending antitrust litigation, the SDC arbitration and the Israeli tax assessment, as well as the realization of deferred tax assets.